Department of Microbiology, The Madras Medical Mission, 4-A, Mogappair, Chennai, Tamil Nadu 600037, India.
Department of Bio & Nano Technology, Nitte (Deemed to be University), Nitte University Centre for Science Education and Research, Paneer Campus, Deralakatte, Mangaluru 575018, India.
J Appl Microbiol. 2024 Jul 2;135(7). doi: 10.1093/jambio/lxae172.
AIM: Colistin serves as the drug of last resort for combating numerous multidrug-resistant (MDR) Gram-negative infections. Its efficacy is hampered by the prevalent issue of colistin resistance, which severely limits treatment options for critically ill patients. Identifying resistance genes is crucial for controlling resistance spread, with horizontal gene transfer being the primary mechanism among bacteria. This study aimed to assess the prevalence of plasmid-mediated mcr genes associated with colistin resistance in Gram-negative bacteria, utilizing both genotypic and phenotypic tests. METHODS AND RESULTS: The clinical isolates (n = 913) were obtained from a tertiary care center in Chennai, India. Colistin resistance was seen among Gram-negative isolates. These strains underwent screening for mcr-1, mcr-3, mcr-4, and mcr-5 genes via conventional PCR. Additionally, mcr-positive isolates were confirmed through Sanger sequencing and phenotypic testing. The bacterial isolates predominantly comprised Klebsiella pneumoniae (62.43%), Escherichia coli (19.71%), Pseudomonas aeruginosa (10.73%), and Acinetobacter baumannii (4.81%), along with other species. All isolates exhibited multidrug resistance to three or more antibiotic classes. Colistin resistance, determined via broth microdilution (BMD) using CLSI guidelines, was observed in 13.08% of the isolates studied. Notably, mcr-5 was detected in K. pneumoniae in PCR, despite its absence in Sanger sequencing and phenotypic tests (including the combined-disk test, colistin MIC in the presence of EDTA, and Zeta potential assays). This finding underscores the importance of employing multiple diagnostic approaches to accurately identify colistin resistance mechanisms.
目的:多黏菌素被用作治疗多种多重耐药(MDR)革兰氏阴性感染的最后手段。其疗效受到普遍存在的多黏菌素耐药问题的阻碍,这严重限制了重症患者的治疗选择。鉴定耐药基因对于控制耐药传播至关重要,水平基因转移是细菌之间的主要机制。本研究旨在利用基因分型和表型试验评估革兰氏阴性菌中与多黏菌素耐药相关的质粒介导 mcr 基因的流行率。
方法和结果:从印度钦奈的一家三级护理中心获得了临床分离株(n=913)。革兰氏阴性分离株中存在多黏菌素耐药。这些菌株通过常规 PCR 进行 mcr-1、mcr-3、mcr-4 和 mcr-5 基因的筛选。此外,通过 Sanger 测序和表型试验确认 mcr 阳性分离株。细菌分离株主要包括肺炎克雷伯菌(62.43%)、大肠杆菌(19.71%)、铜绿假单胞菌(10.73%)和鲍曼不动杆菌(4.81%),以及其他物种。所有分离株对三种或更多类别的抗生素均表现出多药耐药性。通过 CLSI 指南使用肉汤微量稀释(BMD)测定,研究中 13.08%的分离株表现出多黏菌素耐药。值得注意的是,尽管在 Sanger 测序和表型试验(包括联合药敏试验、EDTA 存在时的多黏菌素 MIC 以及 Zeta 电位测定)中未检测到 mcr-5,但在 PCR 中检测到其存在于肺炎克雷伯菌中。这一发现强调了采用多种诊断方法来准确识别多黏菌素耐药机制的重要性。
Antimicrob Agents Chemother. 2017-5-24
Front Cell Infect Microbiol. 2021
Rev Soc Bras Med Trop. 2019-9-5